Last reviewed · How we verify
current insulin
Insulin replaces or supplements the body's own insulin to regulate blood glucose by promoting glucose uptake into cells and storage as glycogen.
Insulin replaces or supplements the body's own insulin to regulate blood glucose by promoting glucose uptake into cells and storage as glycogen. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents are insufficient).
At a glance
| Generic name | current insulin |
|---|---|
| Also known as | short-acting analog insulin |
| Sponsor | Kinderkrankenhaus auf der Bult |
| Drug class | Insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin is a peptide hormone that binds to insulin receptors on cell surfaces, enabling glucose transport into muscle, fat, and liver cells. This lowers blood glucose levels and promotes anabolic metabolism. Current insulin formulations include rapid-acting, short-acting, intermediate-acting, and long-acting variants designed to mimic physiological insulin secretion patterns.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (when oral agents are insufficient)
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity (PHASE2)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- Technology Intensified Diabetes Education Study in African Americans (NA)
- Blood Glucose Target Before and During Exercise in Adults With Type 1 Diabetes Using an Artificial Pancreas (NA)
- A 12-week Pilot Nutrition Intervention for Children With New Diagnosis of Stage 3 Type 1 Diabetes (T1D) (NA)
- Study of Peripheral Arterial Disease (PAD) in People With Cancer Who Will Be Having Surgery
- Closed Loop and Education for Hypoglycemia Awareness Restoration (NA)
- Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- current insulin CI brief — competitive landscape report
- current insulin updates RSS · CI watch RSS
- Kinderkrankenhaus auf der Bult portfolio CI